>
Switch to:

Turning Point Therapeutics EV-to-EBIT

: -16.87 (As of Today)
View and export this data going back to 2019. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Turning Point Therapeutics's Enterprise Value is $2,281.85 Mil. Turning Point Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 was $-135.26 Mil. Therefore, Turning Point Therapeutics's EV-to-EBIT for today is -16.87.

NAS:TPTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.23   Med: -27.06   Max: -15.28
Current: -16.87

-33.23
-15.28

During the past 4 years, the highest EV-to-EBIT of Turning Point Therapeutics was -15.28. The lowest was -33.23. And the median was -27.06.

NAS:TPTX's EV-to-EBIT is ranked lower than
99.99% of the 271 Companies
in the Biotechnology industry.

( Industry Median: 30.17 vs. NAS:TPTX: -16.87 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Turning Point Therapeutics's Enterprise Value for the quarter that ended in Mar. 2021 was $3,537.89 Mil. Turning Point Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 was $-135.26 Mil. Turning Point Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2021 was -3.82%.


Turning Point Therapeutics EV-to-EBIT Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics Annual Data
Dec17 Dec18 Dec19 Dec20
EV-to-EBIT - - -23.58 -29.74

Turning Point Therapeutics Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.73 -14.35 -21.76 -29.74 -26.16

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Turning Point Therapeutics EV-to-EBIT Distribution

* The bar in red indicates where Turning Point Therapeutics's EV-to-EBIT falls into.



Turning Point Therapeutics EV-to-EBIT Calculation

Turning Point Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2281.849/-135.259
=-16.87

Turning Point Therapeutics's current Enterprise Value is $2,281.85 Mil.
Turning Point Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 was -32.732 (Jun. 2020 ) + -18.539 (Sep. 2020 ) + -47.939 (Dec. 2020 ) + -36.049 (Mar. 2021 ) = $-135.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turning Point Therapeutics  (NAS:TPTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Turning Point Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2021 ) =EBIT / Enterprise Value (Q: Mar. 2021 )
=-135.259/3537.893631
=-3.82 %

Turning Point Therapeutics's Enterprise Value for the quarter that ended in Mar. 2021 was $3,537.89 Mil.
Turning Point Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 was -32.732 (Jun. 2020 ) + -18.539 (Sep. 2020 ) + -47.939 (Dec. 2020 ) + -36.049 (Mar. 2021 ) = $-135.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turning Point Therapeutics EV-to-EBIT Related Terms


Turning Point Therapeutics EV-to-EBIT Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)